Perspective Therapeutics to Participate at Upcoming May Investor Conferences
May 03 2024 - 7:00AM
Perspective Therapeutics, Inc. (“Perspective” or “the
Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that
is pioneering advanced treatment applications for cancers
throughout the body, today announced that members of its senior
leadership team will participate in the following upcoming investor
conferences as scheduled below, and will be available for
one-on-one meetings with investors.
Guggenheim Healthcare Talks |
Radiopharmaceuticals DayDate: Monday, May 13,
2024Location: New York, NY
Format: Panel Discussion - Evolving Landscape of
Radiopharmaceuticals in IndustryTime: Noon
Format: Company PresentationTime: 2 p.m. ET
2024 RBC Capital Markets Global
Healthcare ConferenceDate: Wednesday, May 15,
2024Location: New York, NYFormat: Fireside ChatTime: 9.30 a.m.
ET
Bank of America Health Care Conference
2024Date: Wednesday, May 15, 2024Location: Las Vegas,
NVFormat: Fireside ChatTime: 10 a.m. PT / 1 p.m. ET
Cantor’s Frontiers in Radiopharma
Virtual SummitDate: Monday, May 20, 2024Location:
VirtualFormat: Fireside ChatTime: TBD
William Blair’s 3rd Virtual Radiopharma
ConferenceDate: Wednesday, May 22, 2024Location:
VirtualFormat: Fireside ChatTime: 11 a.m. ET
Webcast events can be accessed live, and replays
will be archived for 90 days and available through the Investors
page on the Perspective website.
About Perspective Therapeutics,
Inc.Perspective Therapeutics, Inc., is a
radiopharmaceutical development company that is pioneering advanced
treatment applications for cancers throughout the body. The Company
has proprietary technology that utilizes the alpha emitting isotope
212Pb to deliver powerful radiation specifically to cancer cells
via specialized targeting peptides. The Company is also developing
complementary imaging diagnostics that incorporate the same
targeting peptides which provide the opportunity to personalize
treatment and optimize patient outcomes. This "theranostic"
approach enables the ability to see the specific tumor and then
treat it to potentially improve efficacy and minimize toxicity.
The Company's melanoma (VMT01) and
neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a
imaging and therapy trials for the treatment of metastatic melanoma
and neuroendocrine tumors at several leading academic institutions.
The Company has also developed a proprietary 212Pb generator to
secure key isotopes for clinical trial and commercial
operations.
For more information, please visit the Company's
website at www.perspectivetherapeutics.com.
Safe Harbor StatementThis press
release contains forward-looking statements within the meaning of
the United States Private Securities Litigation Reform Act of 1995.
Statements in this press release that are not statements of
historical fact are forward-looking statements. Words such as
“may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “estimate,” “believe,” “predict,”
“potential” or “continue” or the negative of these terms or other
similar expressions are intended to identify forward-looking
statements, though not all forward-looking statements contain these
identifying words. Forward-looking statements in this press release
include statements concerning, among other things, the Company’s
ability to pioneer advanced treatment applications for cancers
throughout the body; the Company's prediction that complementary
imaging diagnostics that incorporate certain targeting peptides
provide the opportunity to personalize treatment and optimize
patient outcomes; the Company's expectation that its "theranostic"
approach enables the ability to see specific tumors and then treat
it to potentially improve efficacy and minimize toxicity; the
Company’s ability to develop a proprietary 212Pb generator to
secure key isotopes for clinical trial and commercial operations;
the Company’s clinical development plans and the expected timing
thereof; the expected timing for availability and release of data;
expectations regarding the potential market opportunities for the
Company’s product candidates; the potential functionality,
capabilities, and benefits of the Company’s product candidates and
the potential application of these product candidates for other
disease indications; the Company’s expectations, beliefs,
intentions, and strategies regarding the future; the Company’s
intentions to improve important aspects of care in cancer
treatment; and other statements that are not historical fact.
The Company may not actually achieve the plans,
intentions or expectations disclosed in the forward-looking
statements and you should not place undue reliance on the
forward-looking statements. These forward-looking statements
involve risks and uncertainties that could cause the Company’s
actual results to differ materially from the results described in
or implied by the forward-looking statements, including, without
limitation, the potential that regulatory authorities may not grant
or may delay approval for the Company’s product candidates;
uncertainties and delays relating to the design, enrollment,
completion, and results of clinical trials; unanticipated costs and
expenses; early clinical trials may not be indicative of the
results in later clinical trials; clinical trial results may not
support regulatory approval or further development in a specified
indication or at all; actions or advice of regulatory authorities
may affect the design, initiation, timing, continuation and/or
progress of clinical trials or result in the need for additional
clinical trials; the Company’s ability to obtain and maintain
regulatory approval for the Company’s product candidates; delays,
interruptions or failures in the manufacture and supply of the
Company’s product candidates; the size and growth potential of the
markets for the Company’s product candidates, and the Company’s
ability to service those markets; the Company’s cash and cash
equivalents may not be sufficient to support its operating plan for
as long as anticipated; the Company’s expectations, projections and
estimates regarding expenses, future revenue, capital requirements,
and the availability of and the need for additional financing; the
Company’s ability to obtain additional funding to support its
clinical development programs; the availability or potential
availability of alternative products or treatments for conditions
targeted by the Company that could affect the availability or
commercial potential of its product candidates; the ability of the
Company to manage growth and successfully integrate its businesses;
the Company’s ability to maintain its key employees; sufficient
training and use of the Company’s products and product candidates;
the market acceptance and recognition of the Company’s products and
product candidates; the Company’s ability to maintain and enforce
its intellectual property rights; the Company’s ability to maintain
its therapeutic isotope supply agreement with the Department of
Energy; the Company’s ability to continue to comply with the
procedures and regulatory requirements mandated by the FDA for
additional trials, Phase 1 and 2 approvals, Fast Track approvals,
and 510(k) approval and reimbursement codes; and any changes in
applicable laws and regulations. Other factors that may cause the
Company’s actual results to differ materially from those expressed
or implied in the forward-looking statements in this press release
are described under the heading “Risk Factors” in the Company’s
most recent Annual Report on Form 10-K filed with the Securities
and Exchange Commission (the “SEC”), in the Company’s other filings
with the SEC, and in the Company’s future reports to be filed with
the SEC and available at www.sec.gov. Forward-looking statements
contained in this news release are made as of this date. Unless
required to do so by law, we undertake no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events, or otherwise.
Media and Investor Relations Contacts:
Perspective Therapeutics IR:
Annie Cheng
ir@perspectivetherapeutics.com
Russo Partners, LLC
Nic Johnson / Adanna G. Alexander, Ph.D.
PerspectiveIR@russopr.com
Perspective Therapeutics (AMEX:CATX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Perspective Therapeutics (AMEX:CATX)
Historical Stock Chart
From Jul 2023 to Jul 2024